Dr. Murck presented at CNS Summit in Boston. His presentation provided proof of concept data on the effect of enoxolone in immunometabolic depression, which frequently shows therapy resistance. It is entitled: "Randomized placebo-controlled proof of concept study of the action of the 11beta-hydroxysteroid-dehydrogenase type 2 (11beta HSD2) and toll like receptor 4 (TLR4) inhibitor glycyrrhetinic acid (enoxolone) in immunometabolic depression".